UpToDate خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده:
4
September 2025
Note: Paser oral packets have been discontinued in the United States for >1 year.
Tuberculosis, drug resistant (alternative agent): Note: Expert consultation for optimal regimen and duration of treatment is advised.
Oral: 4 g two to three times daily as part of an appropriate combination regimen (Ref).
CrCl ≥30 mL/minute: No dosage adjustment necessary (Ref).
CrCl <30 mL/minute: Contraindicated in patients with severe impairment in the manufacturer’s labeling; however, some experts suggest a dose of 4 g twice daily (Ref).
Patients on hemodialysis: Contraindicated in patients with end-stage renal disease in the manufacturer’s labeling; however, some experts suggest a dose of 4 g twice daily, administered after hemodialysis on dialysis days (Ref).
There are no dosage adjustments provided in the manufacturer's labeling; use with caution
Refer to adult dosing.
Tuberculosis (second-line agent):
Children ≤40 kg and Adolescents <15 years: Oral: 200 to 300 mg/kg/day (usually 100 mg/kg/dose 2 to 3 times daily). Note: Use in combination with other antituberculous agents (Ref).
Children >40 kg and Adolescents ≥15 years: Refer to adult dosing.
There are no dosage adjustments provided in the manufacturer's labeling; contraindicated in severe impairment.
There are no dosage adjustments provided in the manufacturer's labeling; contraindicated in severe impairment.
The following adverse drug reactions are derived from product labeling unless otherwise specified.
Frequency not defined:
Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting
Hypersensitivity: Hypersensitivity reaction
Hypersensitivity to aminosalicylic acid or any component of the formulation; severe or end-stage renal disease
Concerns related to adverse effects:
• Salicylate sensitivity: Patients with nasal polyps and asthma may have an increased risk of salicylate sensitivity.
Disease-related concerns:
• Hepatic impairment: Use with caution in patients with hepatic impairment.
• Renal impairment: Use with caution in patients with renal impairment; contraindicated in patients with severe or end-stage renal disease.
Paser oral packets have been discontinued in the United States for >1 year.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Packet, Oral:
Paser: 4 g (30 ea [DSC])
No
Pack (Paser Oral)
4 g (per each): $8.00
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Oral: May be administered with food. Do not use granules if packet is swollen or if granules are discolored (ie, brown or purple). Granules may be sprinkled on applesauce or yogurt (do not chew) or suspended in an acidic beverage (eg, tomato or orange juice).
Oral: Do not use granules if packet is swollen or if granules are discolored (ie, brown or purple). Granules may be sprinkled on applesauce or yogurt (do not chew) or suspended in tomato or orange juice.
Tuberculosis: Treatment of tuberculosis, as part of an appropriate combination regimen, in the setting of multidrug resistance or intolerance to other agents.
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.
Bacillus Calmette Guerin (BCG) (Intravesical): Antibiotics may decrease therapeutic effects of Bacillus Calmette Guerin (BCG) (Intravesical). Risk X: Avoid
Bacillus Calmette Guerin (BCG) (Percutaneous): Antibiotics may decrease therapeutic effects of Bacillus Calmette Guerin (BCG) (Percutaneous). Risk C: Monitor
Bacillus clausii: Antibiotics may decrease therapeutic effects of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider Therapy Modification
Cholera Vaccine: Antibiotics may decrease therapeutic effects of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid
Dapsone (Topical): May increase adverse/toxic effects of Methemoglobinemia Associated Agents. Risk C: Monitor
Fecal Microbiota (Live) (Oral): Antibiotics may decrease therapeutic effects of Fecal Microbiota (Live) (Oral). Risk X: Avoid
Fecal Microbiota (Live) (Rectal): Antibiotics may decrease therapeutic effects of Fecal Microbiota (Live) (Rectal). Risk X: Avoid
Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may decrease therapeutic effects of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor
Lactobacillus and Estriol: Antibiotics may decrease therapeutic effects of Lactobacillus and Estriol. Risk C: Monitor
Local Anesthetics: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor
Mycophenolate: Antibiotics may decrease active metabolite exposure of Mycophenolate. Specifically, concentrations of mycophenolic acid (MPA) may be reduced. Risk C: Monitor
Nitric Oxide: May increase adverse/toxic effects of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor
Prilocaine: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor for signs of methemoglobinemia when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid use of these agents with prilocaine/lidocaine cream in infants less than 12 months of age. Risk C: Monitor
Primaquine: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Primaquine. Specifically, the risk for methemoglobinemia may be increased. Management: Avoid concomitant use of primaquine and other drugs that are associated with methemoglobinemia when possible. If combined, monitor methemoglobin levels closely. Risk D: Consider Therapy Modification
RifAMPin: Aminosalicylic Acid may decrease serum concentration of RifAMPin. Risk C: Monitor
Sodium Nitrite: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor
Sodium Picosulfate: Antibiotics may decrease therapeutic effects of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider Therapy Modification
Tenofovir Disoproxil Fumarate: Aminosalicylic Acid may decrease serum concentration of Tenofovir Disoproxil Fumarate. Risk C: Monitor
Typhoid Vaccine: Antibiotics may decrease therapeutic effects of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider Therapy Modification
Untreated tuberculosis (TB) disease (active TB) is associated with an increased risk of adverse pregnancy outcomes, including low birth weight infants, preterm birth, miscarriage, and perinatal death. Adverse maternal outcomes include an increased risk of anemia, preeclampsia, eclampsia, and sepsis. Placental TB transmission may also occur (congenital TB) (Hui 2022; Maugans 2023; Miele 2020).
Treatment of multidrug-resistant TB during pregnancy should be individualized. The selection of second-line agents (such as aminosalicylic acid) should be made as part of a shared decision-making process (ATS/CDC/ERS/IDSA [Nahid 2019]).
Aminosalicylic acid is present in human milk.
Following the administration of oral aminosalicylic acid 4 g to a lactating woman (postpartum age not presented), peak maternal serum concentrations were 70.1 mcg/mL at 1 hour, peak breast milk concentrations were 1.1 mcg/mL at 3 hours, and the half-life of aminosalicylic acid in the breast milk was calculated to be 2.5 hours (Holdiness 1984). Using the peak breast milk concentration from this single case report, the relative infant dose (RID) of aminosalicylic acid was calculated to be <1% compared to an infant therapeutic dose of 200 to 300 mg/day (Tran 1998). In general, breastfeeding is considered acceptable when the RID of a medication is <10% (Anderson 2016; Ito 2000). Because information is limited, monitor infants exposed to aminosalicylic acid via breast milk for adverse events such as anorexia, diarrhea, nausea, vomiting, or hypersensitivity reactions (Tran 1998).
Options for infant feeding during therapy for drug-resistant tuberculosis should be considered as part of a shared decision-making process (Loveday 2020). Transmission of Mycobacterium tuberculosis does not occur via breast milk; however, patients with TB disease (active TB) who are infectious should take precautions when in close contact with their infant to prevent airborne transmission (Loveday 2020; Maugans 2023).
Liver function; thyroid function; CBC; serum electrolytes (AST/CDC/ERS/IDSA [Nahid 2019]); serum concentrations (peak) as clinically indicated (Asultan 2014).
Timing of serum samples: Draw peak approximately 6 hours postdose (Alsultan 2014).
Therapeutic level: Peak: 20 to 60 mcg/mL; consider dose increase if <10 mcg/mL (Alsultan 2014).
Aminosalicylic acid (PAS) is a highly-specific bacteriostatic agent active against M. tuberculosis. Structurally related to para-aminobenzoic acid (PABA) and its mechanism of action is thought to be similar to the sulfonamides, a competitive antagonism with PABA; disrupts plate biosynthesis in sensitive organisms.
Absorption: Readily, >90%
Protein binding: 50% to 60%
Metabolism: Hepatic (>50%) via acetylation
Half-life elimination: Reduced with renal impairment
Time to peak, serum: 6 hours
Excretion: Urine (>80% as unchanged drug and metabolites)
Altered kidney function: Drug and its acetyl metabolite may accumulate.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
